Log In
BCIQ
Print this Print this
 

Salagen, pilocarpine (KSS-694)

  Manage Alerts
Collapse Summary General Information
Company Eisai Co. Ltd.
DescriptionPilocarpine tablets
Molecular Target Muscarinic receptor
Mechanism of ActionMuscarinic receptor agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationXerostomia
Indication DetailsTreat dry mouth in patients with Sjogren's syndrome; Treat radiation-induced dry mouth in head and neck cancer patients; Treat xerostomia
Regulatory Designation
PartnerKissei Pharmaceutical Co. Ltd.;
Merus Labs International Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$29.5M

$29.5M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/22/2015

$29.5M

$29.5M

0

Get a free BioCentury trial today